UNRIVALED COMMITMENT TO QUALITY CHOICE CONFIDENCE

Activa™ Product Portfolio for Deep Brain Stimulation
YOUR
DBS PORTFOLIO
SOLUTION

FROM PLANNING TO PROGRAMMING

We’ve got you covered across every step of the DBS procedure, from planning to programming. Supporting your work to raise the standard of care and optimize operational efficiencies — with our Unrivaled Commitment.

StealthStation™ S8 Surgical Navigation System
O-arm™ Surgical Imaging System

Activa® DBS System
CHOICE

The Broadest, Full-Body MR Conditional DBS Portfolio with Advanced Programming Options and the most indications.

Activa™ Neurostimulators
Our third generation of devices developed with you and your patients need for choice and confidence in mind. The Activa™ family of devices offers the choice of three different neurostimulators across a standardized platform of features and familiar programming options. Backed with the confidence of our 25 year legacy in DBS.

**Activa™ PC**
Dual-channel, primary cell neurostimulator used for patients with moderate energy needs. Indicated for treating Parkinson’s Disease, Essential Tremor, Dystonia,* OCD* and Epilepsy.

**Activa™ SC**
Single-channel, primary cell neurostimulator used for patients with moderate energy needs. Indicated for treating Parkinson’s Disease, Essential Tremor, Dystonia,* and OCD*.

**Activa™ RC**
Dual-channel, rechargeable neurostimulator with 15 year longevity** used for patients with high energy needs. Indicated for the treatment of Parkinson’s Disease and Essential Tremor.

**DBS Clinician Programmer**
The power to streamline your programming session with freer motion, a fluid interface, and insightful patient data — so you and your DBS patients can experience an altogether smarter therapeutic journey.

**Patient Programmer**
Both the TH90D01 Medtronic DBS™ patient programmer and the 37441 Medtronic Intercept™ patient programmer can be set to operate in a Simple or Advanced mode, as assigned by the managing clinician to address multiple patient needs. Epilepsy features such as the seizure key are available ONLY with the Intercept Patient Programmer (37441). The TH90D01 is not indicated for Epilepsy.

*Humanitarian Device: The effectiveness of these devices for the treatment of dystonia and obsessive-compulsive disorder has not been demonstrated.

**Activa™ RC devices eligible for the service life extension and the supplemental limited warranty are those devices sold in the U.S. that have been successfully interrogated with the Medtronic Activa Clinician Programmer (tablet) prior to reaching End of Service (EOS).
## Quality

To best serve you and your patients, we need a thorough understanding of how our devices perform, not only in the lab, but also in real life. That's why we have tracked more than 2,100 patients and have logged 12,000 years of device experience from multiple locations around the globe.

Find more information in our annual Product Performance report.

https://professional.medtronic.com/ppr

---

### Neurostimulators

| Model | Number/Product Name | Devices Enrolled | Device Events | Cumulative Follow-up | 1 yr | 2 yrs | 3 yrs | 4 yrs | 5 yrs | 6 yrs | 7 yrs | 8 yrs | 9 yrs | 10 yrs | 11 yrs |
|-------|---------------------|------------------|---------------|---------------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Activa™ PC | 1,865 | 21 | 37,204 | 99.2% | 98.8% | 98.8% | 98.4% | 98.4% | - | - | - | - |
| Activa™ SC | 814 | 6 | 15,817 | 99.3% | 99.0% | 99.0% | 99.0% | - | - | - | - |
| Activa™ RC | 364 | 5 | 7,249 | 99.1% | 98.4% | 97.5% | 97.5% | - | - | - | - |

* This table shows the percentage of implanted devices that remain free from product performance-related events at various time points.

† There were a total of 34 neurostimulator-related events reported to the registry, but only 32 events are included in this summary table. The remaining 2 events were attributable to other non-Activa models not included on this table.

‡ There were a total of 98 lead-related product performance events reported to the registry, but only 69 events included in this summary table. The remaining lead-related events occurred in a lead model for which no device survival data are presented due to an insufficient number of enrolled devices (n=3) or were subsequent events that did not affect the device survival estimates.

§ There were a total of 42 extension-related product performance events reported to the registry, but only 32 events included in this summary table. The remaining events occurred in an extension model for which no device data are presented due to an insufficient number of enrolled devices (n=7) or were subsequent events that did not affect the device survival estimates or attributable to other models not included on this table.

| Model | Number/Product Name | Devices Enrolled | Device Events | Cumulative Follow-up | 1 yr | 2 yrs | 3 yrs | 4 yrs | 5 yrs | 6 yrs | 7 yrs | 8 yrs | 9 yrs | 10 yrs | 11 yrs |
|-------|---------------------|------------------|---------------|---------------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Model 3387 | 1,693 | 17 | 40,644 | 99.3% | 99.1% | 99.1% | 99.1% | 97.4% | 97.4% | 97.4% | 97.4% | 96.0% | 96.0% | 94.1% | 94.1% |
| Model 3389 | 2,310 | 52 | 55,327 | 98.8% | 98.1% | 97.3% | 96.1% | 95.0% | 92.4% | 91.8% | 91.1% | 91.1% | 89.8% | 89.8% | 89.8% |

### Leads

| Model | Number/Product Name | Devices Enrolled | Device Events | Cumulative Follow-up | 1 yr | 2 yrs | 3 yrs | 4 yrs | 5 yrs | 6 yrs | 7 yrs | 8 yrs | 9 yrs | 10 yrs | 11 yrs |
|-------|---------------------|------------------|---------------|---------------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Model 37086 | 3,503 | 32 | 80,005 | 99.5% | 99.1% | 98.9% | 98.8% | 97.8% | 97.8% | - | - | - | - |

<table>
<thead>
<tr>
<th>Group</th>
<th>Voltage</th>
<th>Frequency</th>
<th>Impedance</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>2.0 V, 120 µs</td>
<td>130 Hz</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>3.6 V, 120 µs</td>
<td>130 Hz</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>3.6 V, 120 µs</td>
<td>130 Hz</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>2.0 V, 120 µs</td>
<td>130 Hz</td>
<td></td>
</tr>
</tbody>
</table>

In Advanced Mode, patients may select from up to four clinician-programmed Groups. One group might provide better large motor control, for example, while another might help with fine motor skills.

---

## Advanced Programming Features

**Personalize your patients’ DBS therapy.**

You choose the programming mode that is right for your patient. Advanced Mode unlocks the Groups and Advanced Parameter adjust capability. Patients can view therapy settings on their patient programmer screen.

**Groups**

**Patients Can Switch Settings—Without the Office Call**

You can configure up to four sets of therapy settings, or Groups, targeted at specific daily living activities.

Patients can toggle among the Groups or revert to the original settings. This control may give your patients a sense of freedom and empowerment—and let them switch their settings without the office call.

**Interleaving**

**No need to choose between symptoms.**

With Field Contouring and Interleaving, you won’t be forced to trade off effective control of one symptom at the expense of another.

**Voltage Mode or Current Mode**

We offer both—in each of our Activa neurostimulators—so you can choose based on your preferences and clinical needs.

Voltage mode and current mode deliver the same therapy, but respond to changing impedance differently. Impedance, or resistance, increases due to acute scar tissue growth around electrodes. In the early treatment stages, tissue impedance is known to fluctuate.

Our neurostimulators let you choose which power mode is right for which patient and when.
CONFIDENCE

Supporting you at every step

MAKING A DIFFERENCE
150,000+ DBS PATIENTS WORLDWIDE

LEVEL 1 EVIDENCE*
50+ CENTERS
1,200+ PATIENTS AROUND THE GLOBE
Based on 5 randomized controlled trials
*RCTs included Parkinson’s Disease Patients only.

5 INDICATIONS
MORE PATIENT IMPACT
- Parkinson’s Disease
- Epilepsy
- Essential Tremor
- Dystonia*
- Obsessive Compulsive Disorder*

WORLD’S FIRST AND BROADEST PORTFOLIO OF FULL-BODY MR CONDITIONAL DBS SYSTEMS**

WORLDWIDE SUPPORT NETWORK—FOR YOU FOR YOUR PATIENTS

LEVEL 1 EVIDENCE*
50+ CENTERS
1,200+ PATIENTS AROUND THE GLOBE
Based on 5 randomized controlled trials
*RCTs included Parkinson’s Disease Patients only.

OUR ACADEMIA
YOUR CUSTOMIZED LEARNING

PRECISION IN THE O.R.

*Humanitarian device. The effectiveness of these devices for dystonia and obsessive compulsive disorder has not been demonstrated.
**Medtronic DBS systems are MR Conditional and safe in the MR environment as long as certain conditions are met. For DBS patients exposed to MRI, a significant risk is tissue lesions from component heating, especially at the lead electrodes, resulting in serious and permanent injury, including coma, paralysis, or death. Refer to product labeling for a complete list of conditions.
Antiepileptic medications. Partial-onset seizures, with or without secondary generalization, are refractory to three or more antiepileptic medications. The Medtronic DBS System for Epilepsy has demonstrated safety and effectiveness for patients who average six or more seizures per month over the three most recent months prior to implant of the DBS system (with no more than 30 days between seizures). The Medtronic DBS System for Epilepsy has not been evaluated in patients with less frequent seizures.

Indications:
- **Medtronic DBS Therapy for Parkinson’s Disease**: Bilateral stimulation of the internal globus pallidus (IGP) or the subthalamic nucleus (STN) using Medtronic DBS Therapy for Parkinson’s Disease is indicated for adjunctive therapy in reducing some of the symptoms in individuals with levodopa-responsive Parkinson’s disease of at least 4 years’ duration that are not adequately controlled with medication, including motor complications of recent onset (from 4 months to 3 years) or motor complications of longer-standing duration.
- **Medtronic DBS Therapy for Tremor**: Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) using Medtronic DBS Therapy for Tremor is indicated for the suppression of tremor in the upper extremity. The system is intended for patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability.
- **Medtronic Reclaim™ DBS Therapy for Obsessive-Compulsive Disorder**: Bilateral stimulation of the anterior limb of the internal capsule, AIC, using Medtronic Reclaim™ DBS Therapy is indicated as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive-compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs).
- **Medtronic DBS Therapy for Epilepsy**: Bilateral stimulation of the anterior nucleus of the thalamus (ANT) using the Medtronic DBS System for Epilepsy is indicated as an adjunctive therapy for reducing the frequency of seizures in individuals 18 years of age or older diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary generalization, that are refractory to three or more antiepileptic medications.

Contraindications/Warnings/Precautions:
- Use of a full body transmit radio-frequency (RF) coil, a receive-only head coil, or a head transmit coil that extends over the chest area is contraindicated for patients with the following implanted DBS systems or system components: Soletra™ Model 7426 Neurostimulator; Kinetra™ Model 7428 Neurostimulator; Activa™ SC Model 37602 Neurostimulator; and Model 64001 and Model 64002 pocket adaptors. Tissue lesions from component heating, especially at the lead electrodes, resulting in serious and permanent injury including coma, paralysis, or death, can occur if a contraindicated MRI scan is performed on a patient with these DBS systems. Other conditions that may cause excessive heating at the lead electrodes which can result in serious injury or death, or that may cause device damage, include: neurostimulator implant location other than pectoral and abdominal regions; unapproved MRI parameters; partial system explants (“abandoned systems”); misidentification of neurostimulator model numbers; and broken conductor wires (in the lead, extension or pocket adaptor). Active scan time >30 minutes within a 90 minute window, elevated core/body temperature due to fever or use of blankets, or patient position within the MRI bore other than prone or supine, may cause excessive tissue heating. Leaving therapy on during the scan could increase the potential for uncomfortable, unintended stimulation. Failure to cap a lead-only system may result in unintended stimulation during the scan. External control devices such as the patient programmer, recharger, external neurostimulator and clinician programmer, are MR Unsafe and not allowed in the MRI scanner (magnet) room.

*Humanitarian Device: The effectiveness of these devices for the treatment of dystonia and obsessive-compulsive disorder has not been demonstrated.

USA Rx only  Rev 08/18

StealthStation Cranial™ and O-arm™ Imaging Systems important information:
- Caution: Federal Law (USA) restricts these devices for sale by or on the order of a physician. Refer to product instruction manual/package insert for instructions, warning, precaution and contraindications. For further information, please contact Medtronic ST Neurosurgery at (877) 242-9504, and/or consult medtronic.com/oarm.